Healthcare provider profile · identity verified

Mladen Perak, MD

Internal Medicine · DENVER, CO · NPI 1114908779

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	870	279
Tamsulosin Hcl	Tamsulosin Hcl	406	140
Lisinopril	Lisinopril	395	122
Amlodipine Besylate	Amlodipine Besylate	356	123
Rosuvastatin Calcium	Rosuvastatin Calcium	312	106
Levothyroxine Sodium	Levothyroxine Sodium	310	96
Metformin Hcl	Metformin Hcl	271	92
Simvastatin	Simvastatin	268	84
Gabapentin	Gabapentin	251	94
Pradaxa	Dabigatran Etexilate Mesylate	241	84
Omeprazole	Omeprazole	225	77
Losartan Potassium	Losartan Potassium	204	71
Tramadol Hcl	Tramadol Hcl	180	32
Allopurinol	Allopurinol	172	57
Pantoprazole Sodium	Pantoprazole Sodium	166	61
Atenolol	Atenolol	154	47
Oxycodone Hcl	Oxycodone Hcl	153	32
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	147	25
Metoprolol Tartrate	Metoprolol Tartrate	142	51
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	141	43
Duloxetine Hcl	Duloxetine Hcl	138	52
Albuterol Sulfate Hfa	Albuterol Sulfate	135	72
Warfarin Sodium	Warfarin Sodium	127	38
Glipizide	Glipizide	115	39
Trazodone Hcl	Trazodone Hcl	108	40
Finasteride	Finasteride	107	33
Potassium Chloride	Potassium Chloride	103	34
Furosemide	Furosemide	98	38
Alendronate Sodium	Alendronate Sodium	97	39
Metoprolol Succinate	Metoprolol Succinate	91	32
Doxazosin Mesylate	Doxazosin Mesylate	90	28
Mirtazapine	Mirtazapine	90	38
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	89	25
Hydrochlorothiazide	Hydrochlorothiazide	87	32
Jardiance	Empagliflozin	87	28
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	86	12
Carvedilol	Carvedilol	84	28
Meloxicam	Meloxicam	84	35
Metformin Hcl Er	Metformin Hcl	82	26
Sertraline Hcl	Sertraline Hcl	82	30
Arexvy	Rsvpref3 Antigen/As01e/Pf	79	78
Ozempic	Semaglutide	62	11
Shingrix	Varicella-Zoster Ge/As01b/Pf	62	62
Lorazepam	Lorazepam	59	14
Famotidine	Famotidine	58	22
Fluoxetine Hcl	Fluoxetine Hcl	57	19
Humulin N	Insulin Nph Human Isophane	55	23
Bupropion Xl	Bupropion Hcl	52	17
Citalopram Hbr	Citalopram Hydrobromide	51	15
Wixela Inhub	Fluticasone Propion/Salmeterol	51	22
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	49	14
Fluticasone Propionate	Fluticasone Propionate	48	24
Morphine Sulfate Er	Morphine Sulfate	46	suppressed
Eliquis	Apixaban	45	13
Pregabalin	Pregabalin	45	11
Clopidogrel	Clopidogrel Bisulfate	44	14
Pravastatin Sodium	Pravastatin Sodium	44	14
Triamcinolone Acetonide	Triamcinolone Acetonide	44	30
Estradiol	Estradiol	43	16
Lidocaine	Lidocaine	41	21
Prednisone	Prednisone	40	23
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	39	39
Propranolol Hcl	Propranolol Hcl	38	12
Ezetimibe	Ezetimibe	35	13
Alprazolam	Alprazolam	32	suppressed
Alvesco	Ciclesonide	32	18
Lovastatin	Lovastatin	32	suppressed
Cefuroxime	Cefuroxime Axetil	30	24
Spiriva Respimat	Tiotropium Bromide	30	12
Clonazepam	Clonazepam	29	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	29	16
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	29	13
Spironolactone	Spironolactone	29	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	28	26
Venlafaxine Hcl Er	Venlafaxine Hcl	27	11
Azelastine Hcl	Azelastine Hcl	26	13
Baclofen	Baclofen	25	suppressed
Repatha Sureclick	Evolocumab	24	suppressed
Verapamil Er	Verapamil Hcl	23	suppressed
Amoxicillin	Amoxicillin	22	suppressed
Ipratropium Bromide	Ipratropium Bromide	22	suppressed
Colchicine	Colchicine	21	suppressed
Hydrocortisone	Hydrocortisone	21	12
Memantine Hcl	Memantine Hcl	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Buspirone Hcl	Buspirone Hcl	20	suppressed
Clobetasol Propionate	Clobetasol Propionate	20	suppressed
Donepezil Hcl	Donepezil Hcl	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	11
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	19	suppressed
Solifenacin Succinate	Solifenacin Succinate	19	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	19	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	18	suppressed
Testosterone Cypionate	Testosterone Cypionate	18	suppressed
Trospium Chloride	Trospium Chloride	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Nitroglycerin	Nitroglycerin	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	12
Testosterone	Testosterone	15	suppressed
Cholestyramine	Cholestyramine (With Sugar)	14	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	suppressed
Humulin R	Insulin Regular, Human	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Risperidone	Risperidone	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	11	suppressed
Vancomycin Hcl	Vancomycin Hcl	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error